Sorafenib Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 200 mg
Reference Brands: Nexavar® (US & EU)
Category:
Oncology Cancer Care
Sorafenib is an oral kinase inhibitor used to treat advanced liver cancer (HCC), renal cell carcinoma (RCC), and thyroid cancer. Available in 200 mg tablets under the brand Nexavar® in the US and EU, it blocks tumor cell growth and angiogenesis. Ideal for B2B pharma distributors.
Sorafenib is available in Tablet
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sorafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sorafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sorafenib is a targeted therapy used in the treatment of advanced liver cancer (HCC), renal cell carcinoma (RCC), and thyroid cancer. As an oral kinase inhibitor, it works by blocking tumor cell proliferation and angiogenesis. Available under the brand name Nexavar®, it is marketed in 200 mg tablets in both the US and EU. Sorafenib is a critical component in the treatment of various solid tumors and is manufactured under GMP-compliant standards. Ideal for B2B pharmaceutical partners, it is supplied globally for oncology distributors and hospital tender markets seeking reliable oncology treatments.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing